The Federal Trade Commission has taken aim against a private-equity firms’ healthcare deal in a move regulators say could spell trouble for other healthcare agreements the agency deems anticompetitive, The Wall Street Journal reported recently.
FTC targeting healthcare private equity deals: What ASCs need to know
